Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-09-24Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-09-23Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male miceFrontiers in Pharmacology · 2026-09-22A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy AdultsPharmaceuticals · 2026-09-21Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2026-09-19Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation serviceFrontiers in Public Health · 2026-09-16Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative reviewFrontiers in Psychiatry · 2026-09-155-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.Chinese medical journal · 2026-09-15Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-09-15Lifetime classic psychedelics use is associated with positive environmental attitudes and adopting a vegetarian dietScientific Reports · 2026-09-11Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network OrganizationAnesthesia Research · 2026-09-11Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic ReviewInternational Journal of Molecular Sciences · 2026-09-10Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCDFrontiers in Psychiatry · 2026-09-08One dose of Psilocybin modulates Brain Activity among Depressive patients: Preliminary Neuroimaging Results from the PSILODAC StudyEuropean psychiatry: the journal of the Association of European Psychiatrists · 2026-09-04Psilocybin and Affective Function in Chronic Lower Back Pain DepressionClinicalTrials.gov · 2026-09-04Single-crystal structure determination of psilocybin after dehydration.Acta crystallographica. Section C, Structural chemistry · 2026-09-01HORMONAL MODULATION OF PSILOCYBIN RESPONSIVITY ACROSS THE FEMALE REPRODUCTIVE LIFESPANInternational Journal of Innovative Technologies in Social Science · 2026-08-31PSYCHEDELICS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER AND DEPRESSION: A REVIEW OF CLINICAL TRIALSInternational Journal of Innovative Technologies in Social Science · 2026-08-31Distinct response of resting-state brain networks to psilocybin in autismmedRxiv · 2026-08-22Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-08-21Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin ServicesJAMA Network Open · 2026-08-19Sex Differences in Acute Responses to Psychedelics: Evidence for Greater Subjective Intensity and Impairment in Female ParticipantsbioRxiv · 2026-08-19Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-08-19The Abuse Liability of Classic Psychedelics: A Methodological Critique and Assessment of the Quality of Evidence of Recent StudiesCurrent Addiction Reports · 2026-08-18Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17Psychedelic integration beyond the verbal: participatory-imaginal processing as a hypothesis-generating therapeutic frameworkFrontiers in Psychiatry · 2026-08-12Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe AnxietyDrugs and Drug Candidates · 2026-08-12Psilocybin acutely dissociates cognitive and affective empathy, with empathic concern predicting persisting positive psychological effectsbioRxiv · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord InjuryClinicalTrials.gov · 2026-08-10Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Cardiovascular safety of psilocybin in psychiatric practice: a narrative reviewEuropean Journal of Clinical Pharmacology · 2026-08-01Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative StudyNeuroethics · 2026-08-01In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocinArchives of Toxicology · 2026-08-01Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysisJournal of Affective Disorders · 2026-08-01The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-08-01Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-30Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-30Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from JamaicaFrontiers in Psychiatry · 2026-07-29Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortexPsychopharmacology · 2026-07-28No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory studyJournal of Psychopharmacology · 2026-07-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23Longitudinal neural and psychological changes following psilocybin under compassion imagery primingFrontiers in Human Neuroscience · 2026-07-22Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitationsBritish Journal of Clinical Pharmacology · 2026-07-21Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosisFrontiers in Public Health · 2026-07-20Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophreniaNeuropsychopharmacology · 2026-07-18A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17The ANCHOR Framework for Psychedelic AccompanimentPsyArXiv · 2026-07-15Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-13Psilocybin-induced behavioral and cellular effectsJournal of Neurogenetics · 2026-07-12Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in miceMolecular Psychiatry · 2026-07-07Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-03Surprising Variability in Tryptamine Profiles of Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions.Journal of fungi (Basel, Switzerland) · 2026-07-02Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research DirectionsInternational Journal of Eating Disorders · 2026-07-02Unmixing the psychedelic connectome: Brain network traits of psilocybinNetwork Neuroscience · 2026-07-02Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic CircuitsHuman Brain Mapping · 2026-07-01Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic reviewJournal of Affective Disorders Reports · 2026-07-01Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholdersPalliative Medicine · 2026-07-01Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-07-01Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participantsNeuropsychopharmacology · 2026-07-01Study Protocol for “Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults”PLOS One · 2026-06-30Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortexJournal of Psychopharmacology · 2026-06-28Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-17Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World ImplementationHealthcare · 2026-06-03Impact of formulation variables on the quality attributes of psilocybin-loaded oral thin films for early-phase developmentJournal of Drug Delivery Science and Technology · 2026-06-01Psilocybin: Chemical Foundations and Emerging Therapeutic PotentialMini-Reviews in Medicinal Chemistry · 2026-06-01Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026-06-01Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal CortexEuropean Journal of Neuroscience · 2026-06-01Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depressionJournal of Affective Disorders · 2026-06-01Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in ratsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-06-01Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysisJournal of Psychedelic Studies · 2026-05-29Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headacheJournal of Psychopharmacology · 2026-05-29A spatiotemporal gating hypothesis for psilocybin plasticity: reconciling the 5-HT₂A-TrkB mechanistic paradoxCell Discovery · 2026-05-29Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-28Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case reportFrontiers in Neuroscience · 2026-05-28Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-27Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorderTranslational Psychiatry · 2026-05-26Ancient Wisdom, Modern Questions: Western and Orthodox Christianity Engage Psychedelic SpiritualityReligions · 2026-05-18Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of CareCurrent Psychiatry Reports · 2026-05-14Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal IdeationThe Journal of Clinical Psychiatry · 2026-05-13Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilizationFrontiers in Psychiatry · 2026-05-13The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-07Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative ReviewJournal of Education, Health and Sport · 2026-05-07The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratusFrontiers in Behavioral Neuroscience · 2026-05-07Human brain changes after first psilocybin useNature Communications · 2026-05-05The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures.Journal of psychopharmacology (Oxford, England) · 2026-05-01Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanismsNeuropharmacology · 2026-05-01Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamineGeneral Hospital Psychiatry · 2026-05-01Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.CNS drugs · 2026-05-01A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back PainClinicalTrials.gov · 2026-04-29Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesiaCommunications Biology · 2026-04-24Case Report: Repeated low doses of psilocybin reduce perceived symptom severity but fail to restore cognitive flexibility in a case of severe obsessive-compulsive disorder: an observational case study of identical twinsFrontiers in Psychiatry · 2026-04-21Effects of a single dose of psilocybin on diet-induced weight loss in obese miceTranslational Psychiatry · 2026-04-14A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experienceFrontiers in Public Health · 2026-04-14Observing the mind under psychedelics: conceptual metaphors used following four once-weekly macrodoses of psilocybinPhilosophical Psychology · 2026-04-10Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administrationNature Communications · 2026-04-10Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants.Science advances · 2026-04-03Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocolsEuropean Neuropsychopharmacology · 2026-04-01Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybinJournal of Clinical Epidemiology · 2026-04-01Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysisNeuroscience & Biobehavioral Reviews · 2026-04-01Regulatory ambiguity and governance challenges for psilocybin mushrooms in BrazilInternational Journal of Drug Policy · 2026-04-01An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness-a psychometric analysis using the PES100 in controlled psychedelic studiesReligion Brain & Behavior · 2026-03-31Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-30Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronseLife · 2026-03-27Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptorsCommunications Biology · 2026-03-26Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)Brain Sciences · 2026-03-26When I use a word... The psychedelic mind’s eyeBMJ · 2026-03-20PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONSInternational Journal of Innovative Technologies in Social Science · 2026-03-19Psilocybin effects on brain functional connectivity: a systematic review of fMRI studiesDiscover Mental Health · 2026-03-19Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distributionCanadian Journal of Public Health · 2026-03-19Explainable AI framework for psilocybin depression treatment optimizationFrontiers in Computer Science · 2026-03-16Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant responsebioRxiv · 2026-03-10Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping reviewJournal of Psychedelic Studies · 2026-03-09“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case reportJournal of Psychedelic Studies · 2026-03-09Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocinMetabolic Engineering · 2026-03-01Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse PreventionAddiction Biology · 2026-03-01Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapyJournal of Affective Disorders · 2026-03-01Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant DepressionValue in Health Regional Issues · 2026-03-01Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applicationsProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2026-03-01Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-02-25Pilot study of psilocybin in patients with post-treatment lyme diseaseScientific Reports · 2026-02-25Psychedelic Healing: Adjunct Therapy Harnessing Opened MalleabilityClinicalTrials.gov · 2026-02-13Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metricsJournal of Psychedelic Studies · 2026-02-12Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12Acute psilocin increased cortical activity in ratFrontiers in Neuroscience · 2026-02-04The effect of psilocin on neurotransmitters release in the claustrum and on rat behaviorPharmacological Reports · 2026-02-01Patient perspectives on research gaps in cluster headache.Headache · 2026-02-01PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSIONInternational Journal of Innovative Technologies in Social Science · 2026-01-28A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild StressJournal of Psychoactive Drugs · 2026-01-02Sex-dependent effects of psychedelics: review of evidence from rodent models.Frontiers in psychiatry · 2026-01-01COMPARATIVE EFFICACY AND ACCEPTABILITY OF PSILOCYBIN-KETAMINE AND TYPICAL ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER MANAGEMENT: A NETWORK META-ANALYSISThe Study of Phenomena Related to Health · 2026-01-01Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacinNeuroscience Applied · 2026-01-01Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study.Journal of addiction medicine · 2026-01-01Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.Journal of psychopharmacology (Oxford, England) · 2026-01-01Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.Neuroscience and biobehavioral reviews · 2026-01-01Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.Journal of psychopharmacology (Oxford, England) · 2026-01-01Retraction: Acute psilocybin increased cortical activities in rats.Frontiers in neuroscience · 2026-01-01The potential of event-related beta oscillations as biomarkers for neuromodulatory treatment efficacy.Frontiers in psychology · 2026-01-01Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology.Frontiers in pharmacology · 2026-01-01Microdosing Psychedelics to Improve MoodClinicalTrials.gov · 2025-12-30Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational StudyResearch Square · 2025-12-10The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female MiceThe Journal of Neuroscience · 2025-12-10Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility StudyClinicalTrials.gov · 2025-12-04Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategyEuropean Journal of Medicinal Chemistry Reports · 2025-12-01Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology · 2025-12-01Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.Harm reduction journal · 2025-11-25Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experiencePsychedelics · 2025-11-20Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics.ACS chemical neuroscience · 2025-11-19Unmixing the Psychedelic Connectome: Brain Network Traits of PsilocybinbioRxiv · 2025-11-17Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Journal of affective disorders · 2025-11-15Structure-Guided Design of Novel 5-HT Partial Agonists as Psychedelic Analogues with Antidepressant Effects.Journal of medicinal chemistry · 2025-10-23Structure-GuidedDesign of Novel 5-HT2A Partial Agonists as PsychedelicAnalogues with Antidepressant EffectsFigshare · 2025-10-15Real-world use of classic and non-classic psychedelics in Hispanic/Latino adults with Obsessive-Compulsive Disorder: International findings from the LATINO Study.UNC Libraries · 2025-10-09Neurocomputational evidence of sustained Self-Other mergence after psychedelicsmedRxiv · 2025-10-08Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathwayNaunyn-Schmiedeberg's Archives of Pharmacology · 2025-10-01S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19Five-year outcomes of psilocybin-assisted therapy for Major Depressive DisorderJournal of Psychedelic Studies · 2025-09-04Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review.Journal of psychopharmacology (Oxford, England) · 2025-09-01Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms.American journal of ophthalmology case reports · 2025-09-01Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and RatsBiological Psychiatry Global Open Science · 2025-09-01Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.PLoS medicine · 2025-09-01Psychedelic minimalism: the case against music in psychedelic therapy settingsFrontiers in Psychiatry · 2025-08-26Effects of Psilocybin in Post-Treatment Lyme DiseaseClinicalTrials.gov · 2025-08-20The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of PsilocinACS Pharmacology & Translational Science · 2025-08-08Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats.Progress in neuro-psychopharmacology & biological psychiatry · 2025-07-13Equitable access to psilocybin-assisted psychotherapy in New Zealand.The New Zealand medical journal · 2025-07-11The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of PsilocinFigshare · 2025-07-08Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.Psychopharmacology · 2025-07-01The Rise of Psilocybin Use in the United States: A Multisource Observational Study.Annals of internal medicine · 2025-07-01Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.JAMA network open · 2025-07-01Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autismMagna Scientia Advanced Research and Reviews · 2025-06-28Psilocybin With Intracranial Neural SensingClinicalTrials.gov · 2025-06-06Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.Psychopharmacology · 2025-06-01Psilocybin's lasting action requires pyramidal cell types and 5-HT receptors.Nature · 2025-06-01Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signalingInternational Immunopharmacology · 2025-06-01Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical PopulationmedRxiv · 2025-05-29Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity.The journal of headache and pain · 2025-05-23ALSUntangled #77: Psilocybin.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025-05-01Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.European journal of anaesthesiology · 2025-05-01Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.Palliative & supportive care · 2025-04-22Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters.Scientific reports · 2025-04-22Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humansScientific Reports · 2025-04-21A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With FibromyalgiaClinicalTrials.gov · 2025-04-16